证券代码：000950 证券简称：重药控股 公告编号：2026-006 重药控股股份有限公司 关于回购股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 公司回购股份的时间、回购股份价格及集中竞价交易的委托时段符合《深圳 证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定，具体情况 如下： 1.公司未在下列期间回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 重药控股股份有限公司（以下简称"公司"）分别于 2025 年 7 月 10 日、2025 年 7 月 28 日召开第九届董事会第十五次会议、2025 年第三次临时股东会，审议 通过了《关于回购公司股份的议案》，同意公司使用自有资金及股票回购专项贷 款，通过深圳证券交易所交易系统以集中竞价交易方式回购公司已发行的人民币 普通股（A 股），用于减少公司注册资本。本次用于回购股份的资金总额不低于 人民币 8,000 万元（含本数），不超过人民币 10,000 ...

Market Overview - The pharmaceutical commercial sector declined by 1.0% on January 28, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - China Medicine (600056) with a closing price of 11.21, up 2.28% and a trading volume of 531,600 shares, totaling 593 million yuan [1] - Yixin Pharmacy (002727) closed at 14.09, up 0.64% with a trading volume of 220,100 shares, totaling 311 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 12.35, down 4.93% with a trading volume of 432,700 shares, totaling 537 million yuan [2] - Saili Medical (603716) closed at 23.29, down 4.71% with a trading volume of 157,600 shares, totaling 374 million yuan [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 528 million yuan from institutional investors, while retail investors saw a net inflow of 603 million yuan [2] - The capital flow for key stocks showed: - China Medicine had a net inflow of 32.15 million yuan from institutional investors, but a net outflow of 15.57 million yuan from retail investors [3] - Shanghai Pharmaceutical (601607) had a net inflow of 9.01 million yuan from institutional investors, with a significant net outflow of 32.51 million yuan from retail investors [3]

Group 1 - The core point of the news is that Chongqing Pharmaceutical Holdings (重药控股) disclosed that seven of its subsidiaries have paid a total of 32.21 million yuan in back taxes and late fees [1] - The seven subsidiaries involved are Qinghai Pharmaceutical Co., Ltd., Inner Mongolia Zhelimeng Pharmaceutical Co., Ltd., Guizhou Pharmaceutical Group Co., Ltd., Guizhou Pharmaceutical Group He Ping Pharmaceutical Co., Ltd., Shaanxi Huashi Pharmaceutical Co., Ltd., Shaanxi Pharmaceutical Co., Ltd., and Chongqing Pharmaceutical Group (Gansu) Co., Ltd. [1] - The company stated that the back taxes and late fees were due to the self-examination of the subsidiaries regarding the income tax benefits enjoyed under the Western Development policy, with 7.46 million yuan due for 2025 and 24.75 million yuan for 2026 [1] Group 2 - For the first three quarters of 2025, Chongqing Pharmaceutical Holdings reported an operating income of 62.2 billion yuan, representing a year-on-year increase of 4.22% [2] - The net profit attributable to shareholders of the listed company was 384 million yuan, showing a year-on-year growth of 31.41% [2]

Core Viewpoint - The A-share market for pharmaceutical retail stocks experienced a collective rise, driven by new government measures aimed at enhancing pharmaceutical services and encouraging retail drug sales [1] Group 1: Market Performance - Pharmaceutical retail stocks such as Renmin Tongtai and Yifeng Pharmacy hit the daily limit up, while Luyuan Pharmaceutical rose over 7%, Daclin increased over 6%, and Jiuzhoutong gained over 5% [1] - Other notable performers included Zhongyao Holdings, Yaoyigou, Haiwang Biological, Hefuchina, and Shuyupingmin, all rising over 4% [1] Group 2: Government Measures - The Ministry of Commerce and nine other departments issued a document proposing improvements in pharmaceutical services, enhancing pharmacy service capabilities, and promoting prescription circulation to improve the purchasing experience [1] - Measures include optimizing outpatient service coordination for designated retail pharmacies and encouraging retail drug companies to participate in centralized drug procurement [1] - The government is promoting horizontal mergers and acquisitions among retail drug companies and encouraging the sale of innovative drugs and reference preparations through retail channels [1] - There is an emphasis on encouraging e-pharmacy platforms to open data interfaces and strengthen the monitoring of price linkages between online and offline drug retail prices and provincial procurement platform prices [1]

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

Core Viewpoint - The retail pharmacy sector experienced a significant rise in stock prices following the release of a government policy aimed at promoting high-quality development in the pharmaceutical retail industry [1] Group 1: Policy Impact - On January 22, the Ministry of Commerce and nine other departments issued guidelines to encourage horizontal mergers and acquisitions in the pharmaceutical retail sector [1] - The policy aims to optimize the business environment for retail pharmacies, including streamlining the application process for drug operating licenses for consolidated chain or standalone pharmacies [1] - It promotes the integration of wholesale and retail operations to enhance supply chain efficiency and reduce operational costs through shared logistics resources and collaborative quality management systems [1] Group 2: Market Outlook - According to Guojin Securities, leading compliant pharmacy chains are expected to benefit first from the ongoing regulatory push for industry standardization [1] - Companies that have proactively adjusted their store operations are projected to see a marginal recovery in revenue by the third quarter of 2025 [1] - Some leading companies are beginning to explore non-pharmaceutical product offerings, which could become a significant source of profit if they exceed expectations in performance [1]

格隆汇1月22日丨重药控股(000950.SZ)公布，公司下属子公司青海省医药有限责任公司、重药控股哲里 木盟医药（内蒙古）有限公司、贵州省医药（集团）有限责任公司、贵州省医药（集团）和平医药有限 公司、陕西华氏医药有限公司、重药控股陕西医药有限公司、重庆医药集团（甘肃）有限公司，共计7 家企业根据各自主管税务部门的通知，经自查需补缴前期所享受的西部大开发企业所得税优惠税款及滞 纳金总计3221.03万元，其中2025年补缴金额745.80万元，2026年补缴金额2475.23万元。截至本公告披 露日，上述税款及滞纳金已全部缴纳完毕，主管税务部门未对该事项予以处罚。 ...

证券代码：000950 证券简称：重药控股 公告编号：2026-005 重药控股股份有限公司 关于补缴税款的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、基本情况 重药控股股份有限公司（以下简称"公司"）下属子公司青海省医药有限责任 公司、重药控股哲里木盟医药（内蒙古）有限公司、贵州省医药（集团）有限责 任公司、贵州省医药（集团）和平医药有限公司、陕西华氏医药有限公司、重药 控股陕西医药有限公司、重庆医药集团（甘肃）有限公司，共计7家企业根据各 自主管税务部门的通知，经自查需补缴前期所享受的西部大开发企业所得税优惠 税款及滞纳金总计3221.03万元，其中2025年补缴金额745.80万元，2026年补缴金 额2475.23万元。截至本公告披露日，上述税款及滞纳金已全部缴纳完毕，主管 税务部门未对该事项予以处罚。 二、对公司的影响 根据《企业会计准则第 28 号—会计政策、会计估计变更和差错更正》，上 述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据追溯调整。 公司补缴上述税款及滞纳金将分别计入 2025 年、2026 年当期损益，对公 ...

重药控股公告称，下属青海省医药有限责任公司等7家子公司，根据主管税务部门通知，经自查需补缴 前期西部大开发企业所得税优惠税款及滞纳金3221.03万元，其中2025年补缴745.80万元，2026年补缴 2475.23万元，截至公告披露日已全部缴纳，且未受处罚。该事项不属于前期会计差错，不追溯调整前 期财务数据，补缴款将分别计入2025、2026年当期损益，对净利润具体影响以审计后报表为准，不影响 公司正常经营。 ...

（文章来源：证券日报） 证券日报网讯 1月21日，重药控股在互动平台回答投资者提问时表示，截至目前公司业务均发生于国 内。 ...